Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B L Roth

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
Progress in Clinical and Biological Research|January 1, 1985
Evidence for an endacoid for the 5HT2 recognition siteB L Roth, T Nakaki, D M Chuang, et al.
Molecular Pharmacology|August 1, 1997
Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptorsB L Roth, M Shoham, M S Choudhary, et al.
Journal of Neurochemistry|September 1, 1985
5-Hydroxytryptamine uptake and imipramine binding sites in neurotumor NCB-20 cellsT Nakaki, B L Roth, D M Chuang, et al.
European Journal of Pharmacology|November 4, 1986
BAY k 8644, a calcium channel agonist, reverses hypotension in endotoxin-shocked ratsN Ives, J W King, B Chernow, et al.
Pharmacology & Therapeutics|October 17, 1998
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets functionB L Roth, D L Willins, K Kristiansen, et al.
Molecular Pharmacology|October 20, 2000
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5D A Shapiro, K Kristiansen, W K Kroeze, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2001
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptorL Rauser, J E Savage, H Y Meltzer, et al.
Neuroscience|December 4, 2003
The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitroZ Xia, S J Hufeisen, J A Gray, et al.
Journal of Neurochemistry|December 1, 1987
Characterization of two [3H]ketanserin recognition sites in rat striatumB L Roth, S McLean, X Z Zhu, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex modelB L Roth, M S Choudhary, N Khan, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Progress in Clinical and Biological Research|January 1, 1985
Evidence for an endacoid for the 5HT2 recognition siteB L Roth, T Nakaki, D M Chuang, et al.
Molecular Pharmacology|August 1, 1997
Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptorsB L Roth, M Shoham, M S Choudhary, et al.
Journal of Neurochemistry|September 1, 1985
5-Hydroxytryptamine uptake and imipramine binding sites in neurotumor NCB-20 cellsT Nakaki, B L Roth, D M Chuang, et al.
European Journal of Pharmacology|November 4, 1986
BAY k 8644, a calcium channel agonist, reverses hypotension in endotoxin-shocked ratsN Ives, J W King, B Chernow, et al.
Pharmacology & Therapeutics|October 17, 1998
5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets functionB L Roth, D L Willins, K Kristiansen, et al.
Molecular Pharmacology|October 20, 2000
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5D A Shapiro, K Kristiansen, W K Kroeze, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2001
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptorL Rauser, J E Savage, H Y Meltzer, et al.
Neuroscience|December 4, 2003
The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitroZ Xia, S J Hufeisen, J A Gray, et al.
Journal of Neurochemistry|December 1, 1987
Characterization of two [3H]ketanserin recognition sites in rat striatumB L Roth, S McLean, X Z Zhu, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex modelB L Roth, M S Choudhary, N Khan, et al.
Pageof 12